```html

Cutaneous Lupus Erythematosus (CLE)

Overview

Cutaneous lupus erythematosus (CLE) is an autoimmune skin disorder in which the body’s immune system mistakenly attacks healthy skin cells, causing inflammation and a variety of skin lesions. CLE can appear alone (isolated cutaneous lupus) or together with systemic lupus erythematosus (SLE), a disease that affects multiple organs.

• Who it affects: Most commonly seen in women (≈ 90% of cases) between the ages of 20‑50, but men and children can develop CLE.
• Prevalence: Estimates range from 4–8 cases per 100,000 people worldwide. In the United States, about 75 % of patients with SLE also have some form of cutaneous involvement, while isolated CLE occurs in roughly 1.5 % of the general population.<sup>[1] CDC, 2022</sup>
• Types of CLE: The three major clinical sub‑types are
  • Discoid lupus erythematosus (DLE) – the most common, causing scarring plaques.
  • Subacute cutaneous lupus erythematosus (SCLE) – photosensitive, non‑scarring lesions.
  • Acute cutaneous lupus erythematosus (ACLE) – often a “butterfly” rash that appears with systemic disease.

Symptoms

Skin findings vary by subtype, but all share a pattern of inflammation triggered or worsened by sunlight (photosensitivity). Below is a complete symptom list:

Discoid Lupus Erythematosus (DLE)

• Coin-shaped plaques – raised, red, often with a raised border.
• Scaling and crusting – fine or thick scales that may bleed when scratched.
• Follicular plugging – plugs of keratin that give a “carpet‑tack” appearance.
• Scarring – permanent atrophy, pigment loss, or thickened, hardened skin (sclerosis).
• Location – scalp, ears, cheeks, nose, and other sun‑exposed areas.

Subacute Cutaneous Lupus Erythematosus (SCLE)

• Annular or papulosquamous lesions – ring‑shaped or raised patches with scaling.
• Non‑scarring – lesions usually heal without permanent damage.
• Photosensitivity – flare after as little as 15‑30 minutes of sun exposure.
• Location – shoulders, chest, upper back, and arms.

Acute Cutaneous Lupus Erythematosus (ACLE)

• Butterfly rash – erythematous, flat or raised rash over the cheeks and bridge of the nose.
• Malar rash – spares the nasolabial folds, distinguishing it from rosacea.
• Generalized erythema – may involve trunk or extremities.
• Usually transient – appears during disease flares and often disappears with treatment.

Systemic Symptoms (when CLE is associated with SLE)

• Joint pain or swelling
• Fatigue
• Fever
• Kidney, heart, or lung involvement (signs vary; see complications)

Causes and Risk Factors

While the exact trigger for CLE is unknown, research points to a combination of genetic predisposition, environmental exposure, and immune dysregulation.

Genetic Factors

• HLA‑DR2 and HLA‑DR3 alleles are more frequent in patients with lupus.<sup>[2] NIH, 2021</sup>
• First‑degree relatives of people with SLE have a 3‑ to 5‑fold increased risk of developing CLE.

Environmental Triggers

• Ultraviolet (UV) radiation – UVA and UVB cause DNA damage that the immune system mistakenly attacks.
• Medications – certain drugs (e.g., procainamide, thiazide diuretics, and antihypertensives) can induce a lupus‑like skin eruption.
• Smoking – doubles the risk of developing SCLE and worsens response to therapy.<sup>[3] Cleveland Clinic, 2022</sup>
• Infections – viral infections (especially Epstein‑Barr virus) may act as a catalyst.

Hormonal Influences

• Estrogen may amplify immune activity; this partly explains the female predominance.

Other Risk Factors

• Light‑colored skin (Fitzpatrick skin types I‑III) is more photosensitive.
• History of other autoimmune disorders (e.g., rheumatoid arthritis, thyroid disease).

Diagnosis

Diagnosing CLE requires a careful combination of clinical assessment, laboratory testing, and skin biopsy.

Clinical Evaluation

• Detailed history – onset, pattern of lesions, photosensitivity, medication use, systemic symptoms.
• Physical examination – distribution, morphology, and presence of scarring.

Skin Biopsy

A 4‑mm punch biopsy from an active lesion is the gold standard. Pathology typically shows:

• Interface dermatitis with vacuolar changes at the dermal‑epidermal junction.
• Deposits of IgG, IgM, and complement (C3) along the basement membrane (positive “lupus band test”).

Laboratory Tests

• Antinuclear antibody (ANA) – positive in ~70 % of CLE patients; higher titres suggest systemic involvement.
• Anti‑Ro/SSA and Anti‑La/SSB antibodies – especially common in SCLE (up to 80 % positive).
• Complete blood count, renal panel, and urinalysis – to screen for occult systemic lupus.
• Complement levels (C3, C4) – often low in active disease.

Imaging & Other Tests (when systemic disease is suspected)

• Echocardiogram or chest CT for pericardial or pulmonary involvement.
• Renal ultrasound or kidney biopsy if proteinuria is detected.

Treatment Options

Management aims to control skin inflammation, prevent scarring, and reduce the risk of systemic disease. Treatment is individualized based on subtype, severity, and patient preferences.

Topical Therapies

• Corticosteroid creams or ointments (e.g., clobetasol 0.05 %); first‑line for localized lesions.
• Calcineurin inhibitors (tacrolimus 0.1 % ointment or pimecrolimus 1 % cream) – useful for steroid‑sparing.
• Vitamin D analogues (calcipotriene) – may improve hyperpigmented lesions.

Systemic Medications

• Antimalarials – Hydroxychloroquine (200‑400 mg daily) is the cornerstone; improves 70‑80 % of patients.<sup>[4] Mayo Clinic, 2023</sup>
• Quinacrine – added when hydroxychloroquine alone is insufficient.
• Systemic corticosteroids – short courses for severe flares (e.g., prednisone 0.5–1 mg/kg). Long‑term use is avoided due to side effects.
• Immunosuppressants – methotrexate, azathioprine, mycophenolate mofetil for steroid‑refractory disease.
• Biologic agents – belimumab (anti‑BLyS) and rituximab (anti‑CD20) have shown benefit in refractory CLE, though data are limited.

Procedural Options

• Phototherapy (narrow‑band UVB) – paradoxically can improve some lesions when used under strict supervision; not recommended for patients with high photosensitivity.
• Laser therapy – fractional CO₂ lasers can reduce scarring in DLE after lesions are quiescent.
• Excisional surgery – for isolated, well‑circumscribed plaques after disease control.

Lifestyle & Self‑Care

• Broad‑spectrum sunscreen (SPF ≥ 50) applied 15 minutes before sun exposure and reapplied every 2 hours.
• Protective clothing, wide‑brim hats, and UV‑blocking sunglasses.
• Smoking cessation – improves response to antimalarials.
• Stress‑reduction techniques (mindfulness, yoga) – stress can trigger flares.

Living with Cutaneous Lupus Erythematosus

Good day‑to‑day management reduces flares, minimizes scarring, and supports overall well‑being.

Skin‑Care Routine

1. Gentle cleansing – use a mild, fragrance‑free cleanser; avoid scrubbing.
2. Moisturize – apply a hypoallergenic moisturizer within 5 minutes of bathing to lock in moisture.
3. Sun protection – as noted above; consider UV‑protective clothing (UPF 50+).

Medication Adherence

• Take antimalarials with food; monitor for retinal toxicity by having an eye exam at baseline and annually (recommended by AAO).
• Keep a medication log to track side effects.

Monitoring & Follow‑Up

• Dermatology visits every 3–6 months, or sooner if new lesions appear.
• Annual labs (CBC, liver enzymes, kidney function) while on systemic meds.
• Promptly report new joint pain, fever, or swelling – possible systemic involvement.

Psychosocial Support

• Connect with support groups (LUPUS Foundation, local patient networks).
• Consider counseling if facial lesions affect self‑image.

Prevention

Although CLE cannot be completely prevented, risk can be reduced.

• Sun avoidance during peak UV hours (10 am‑4 pm).
• Regular use of high‑SPF sunscreen and protective clothing.
• Smoking cessation – enroll in cessation programs or nicotine‑replacement therapy.
• Review medications with your doctor; avoid known drug‑induced lupus agents when possible.
• Maintain a healthy weight and balanced diet rich in antioxidants (fruits, vegetables, omega‑3 fatty acids) which may modulate inflammation.

Complications

If left untreated or poorly controlled, CLE can lead to several serious problems.

• Permanent scarring and disfigurement – especially with DLE on the face or scalp, potentially causing alopecia.
• Secondary infection – cracked plaques can become colonized with bacteria or fungi.
• Progression to systemic lupus erythematosus – up to 25 % of isolated CLE patients develop systemic disease over a decade.<sup>[5] WHO, 2020</sup>
• Medication toxicity – retinal toxicity from hydroxychloroquine, liver dysfunction from methotrexate, etc.
• Psychological impact – depression, anxiety, and reduced quality of life due to visible skin changes.

When to Seek Emergency Care

---

References:

1. Centers for Disease Control and Prevention. Lupus Data & Statistics. 2022.
2. National Institutes of Health. Genetics of Lupus. 2021.
3. Cleveland Clinic. Smoking and Lupus. 2022.
4. Mayo Clinic. Hydroxychloroquine for Cutaneous Lupus. 2023.
5. World Health Organization. Lupus Erythematosus: Global Burden. 2020.

```